共 50 条
- [31] Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trialINTERNATIONAL JOURNAL OF CANCER, 2023, 152 (08) : 1648 - 1658Jin, ShuilingZhao, RuihuaZhou, ChuangZhong, QianShi, JianxiangSu, ChangLi, QinglongSu, XiaoxingChi, HuabinLu, XuJiang, GuozhongChen, RenyinHan, JinmingJiang, MiaoQiao, ShishiLiu, JingjingSong, MinSong, LijieDu, YabingChang, ZhiweiWang, MengDong, MeilianZhong, YaliYu, PuZhang, XiaojianZong, Hong
- [32] A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell CarcinomaCANCER, 2009, 115 (13) : 2881 - 2890Wuelfing, ChristianMachiels, Jean-Pascal H.Richel, Dirk J.Grimm, Marc-OliverTreiber, UweDe Groot, Marco R.Beuzeboc, PhilippeParikh, RomaPetavy, FrankEl-Hariry, Iman A.
- [33] Combination of anlotinib and irinotecan in the second-line treatment of patients with advanced colorectal cancer: An open-label, multicenter phase I/II study.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Zhang, BoWang, XiZhu, LingjunLi, QunLiu, YunQi, LingShu, YongqianHuang, Jing
- [34] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC)JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)Peer, AvivitNeumann, AvivitKeizrnan, DanielFrank, Stephen JayBerger, RaananLeitzin, LarisaPinto, EsterNeiman, VictoriaRosenbaum, Eli
- [35] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Peer, AvivitNeumann, AvivitKeizman, DanielFrank, Stephen JayBerger, RaananLeitzin, LarisaPinto, EsterNeiman, VictoriaRosenbaum, Eli
- [36] A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and LeiomyosarcomaCLINICAL CANCER RESEARCH, 2022, 28 (23) : 5058 - 5065Chen, Tom Wei-WuHsu, Chia-LangHong, Ruey-LongLee, Jen-ChiehChang, KopingYu, Chih-WeiChen, San-ChiGuo, Jhe-CyuanChen, Mei-LuHsu, Meng-ChiKung, Ting-FangCheng, Ann-LiiYen, Chueh-Chuan
- [37] Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) plus linagliptin (lina) vs ramucirumab (ram) plus paclitaxel (pac) in MORPHEUS-gastric cancerANNALS OF ONCOLOGY, 2021, 32 : S1047 - S1047Lee, J.Ajani, J. A.Chung, H. C.Kang, Y-K.Iqbal, S.Allen, S.Al-Sakaff, N.Decalf, J.Li, S.Pintoffl, J.Sayyed, P.Bang, Y-J.
- [38] Anlotinib plus pemetrexed as a further treatment for patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Chen, JuemingWei, WeiZheng, LieLi, HanFeng, YanlingWan, TingQiu, JiaqiJiang, XingyuXiong, YingZheng, MinLi, JundongHuang, HeSong, LibingLiu, JihongZhang, Yanna
- [39] Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II StudyFRONTIERS IN ONCOLOGY, 2022, 12Cheng, KeWang, YuqingChen, YeZhu, JingjieQi, XiaohuiWang, YachenZou, YanqiuLu, QiuhanLi, Zhiping
- [40] Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): An open-label, single-arm, phase II studyANNALS OF ONCOLOGY, 2024, 35 : S1433 - S1433Wang, Z.Qin, B.Ye, C.Wang, M.Yuan, L.Yao, H.Jiao, X.Liu, K.Sun, L.Dai, W.Ling, Y.Wu, Y.Chen, S.Zhang, Y.Shi, D.Duan, X.Zhong, X.He, X.Zhai, W.Zang, Y.